Stockreport
Is It Time To Reassess Gilead Sciences (GILD) After Its Strong Share Price Run [Yahoo! Finance]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
If you are wondering whether Gilead Sciences is still reasonably priced after its run in recent years, the valuation story is where things get interesting. The share price closed at US$143.93, with returns of 18.4% year to date and 26.0% over the last year, set against shorter term moves of a 3.4% decline over 7 days and a 3.6% decline over 30 days that may hint at changing risk appetite. These recent moves are playing out against a backdrop of ongoing attention on large pharmaceutical names and how investors are weighing long term pipelines against current product portfolios. Market reactions to sector news and shifting sentiment toward established drug makers provide useful context for Gilead Sciences' recent price action. On our valuation checklist, Gilead Sciences scores 4 out of 6 for being undervalued, giving it a value score of . Next we look at how different valuation approaches line up on that score before turning to another way to think about what the stock may be wor
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? [Yahoo! Finance][Yahoo! Finance]
- Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences (GILD) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $180.00 price target on the stock.[MarketBeat]
- ???????????????????? :???????????????2035????2388?2000????????????????????(CAGR)6.0%???????????? [CNET News][CNET News]
- Gilead's BIC LEN HIV Results Highlight Valuation Gap And Future Potential [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- GILD's page on the SEC website
- More